Skip to main content
. Author manuscript; available in PMC: 2017 Oct 11.
Published in final edited form as: J Hypertens. 2016 May;34(5):1005–1010. doi: 10.1097/HJH.0000000000000870

TABLE 3.

Baseline laboratory measures and the results of bivariate analysis for favorable SBP reduction (≥10mmHg) of patients treated with spironolactone

Laboratory measures Favorable SBP reduction
All (n = 79) Yes (n = 54) No (n = 25) P value
Serum creatinine (mg/dl), mean ± SD   1.0 ± 0.3   1.0 ± 0.3   1.0 ± 0.3 0.79
Serum potassium (mEq/24h), mean ± SD   3.7 ± 0.4   3.8 ± 0.4   3.7 ± 0.4 0.38
Glomerular filtration rate (ml/min/1.73m2), mean ± SD   77.6 ± 21.7   75.4 ± 19.4   82.3 ± 25.2 0.19
Serum aldosterone concentration (ng/dl), mean ± SD   14.3 ± 10.1   15.3 ± 11.0 12.2 ± 7.7 0.20
Plasma renin activity (ng/ml/h), mean ± SD   1.7 ± 3.5   1.6 ± 3.8   1.9 ± 3.0 0.73
Aldosterone-to-renin ratio, mean ± SD   22.3 ± 21.7   25.7 ± 24.1   15.0 ± 13.1 0.016
Urinary aldosterone (μg/24 h), mean ± SD   17.2 ± 13.0   18.2 ± 12.7   15.2 ± 13.6 0.35
Urinary sodium (mEq/24h), mean ± SD 200.0 ± 97.4   214.7 ± 101.2 170.2 ± 81.9 0.04
Urinary potassium (mEq/24h), mean ± SD   71.0 ± 36.5   76.5 ± 33.8   58.8 ± 40.1 0.01
Urinary cortisol (μg/24h), mean ± SD   80.3 ± 90.3 102.4 ± 94.7   34.3 ± 59.0 0.0003
Urinary creatinine (mg/24h), mean ± SD 1729.8 ± 646.8 1833.7 ± 667.6 1505.4 ± 546.5 0.04